title: Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
abstract: BACKGROUND
  The SPRINT trial examined efficacy and safety of photochemically treated (PCT) platelets (PLTs). PCT PLTs were equivalent to untreated (control) PLTs for prevention of bleeding. Transfused PLT dose and corrected count increments (CIs), however, were lower and transfusion intervals were shorter for PCT PLTs, resulting in more PCT than control transfusions. PLT dose was analyzed to determine the impact of the number of PLTs transfused on transfusion requirements.
  
  
  METHODS
  Transfusion response was compared for patients with all doses of >or=3.0 x 10(11) and the complementary subset of patients with any dose of fewer than 3.0 x 10(11). Analyses included comparison of bleeding, number of PLT and red blood cell (RBC) transfusions, transfusion intervals, and CIs between PCT and control groups within each PLT dose subset.
  
  
  RESULTS
  Mean PLT dose per transfusion in the PCT group was lower than in the control group (3.7 x 10(11) vs. 4.0 x 10(11); p<0.001). More PCT patients received PLT doses of fewer than 3.0 x 10(11) (n=190) than control patients (n=118; p<0.01). Comparisons of patients receiving comparable PLT doses showed no significant differences between PCT and control groups for bleeding or number of PLT or RBC transfusions; however, transfusion intervals and CIs were significantly better for the control group.
  
  
  CONCLUSIONS
  When patients were supported with comparable doses of PCT or conventional PLTs, the mean number of PLT transfusions was similar. Lower CIs and shorter transfusion intervals for PCT PLTs suggest that some PLT injury may occur during PCT. This injury does not result in a detectable increase in bleeding, however.
authors.affiliation: American Red Cross Blood Services, Philadelphia, Pennsylvania, USA.
authors.forename: Scott
authors.initials: S
authors.lastname: Murphy
authors.forename: Edward
authors.initials: E
authors.lastname: Snyder
authors.forename: Ritchard
authors.initials: R
authors.lastname: Cable
authors.forename: Sherrill J
authors.initials: SJ
authors.lastname: Slichter
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Strauss
authors.forename: Jeffrey
authors.initials: J
authors.lastname: McCullough
authors.forename: Jin-Sying
authors.initials: JS
authors.lastname: Lin
authors.forename: Laurence
authors.initials: L
authors.lastname: Corash
authors.forename: Maureen G
authors.initials: MG
authors.lastname: Conlan
mesh_terms: D000328:Adult; D005260:Female; D011564:Furocoumarins / Q000627:therapeutic use; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D013921:Thrombocytopenia / Q000150:complications / Q000628:therapy*; D014467:Ultraviolet Therapy
chemical_list: D011564:Furocoumarins; C118577:amotosalen